Effect of NT-proBNP Guided Treatment of Chronic Heart Failure
Heart Failure, Congestive
About this trial
This is an interventional diagnostic trial for Heart Failure, Congestive focused on measuring NT-proBNP
Eligibility Criteria
Inclusion Criteria: Admission because of congestive heart failure Elevated NT-proBNP levels on admission Exclusion Criteria: Life-threatening cardiac arrhythmias Urgent intervention Severe lung disease Presence of life threatening disease Signed informed consent for other study Mental or physical status not allowing written informed consent. Unwillingness to give informed consent Patients undergoing haemodialysis or continuous ambulatory peritoneal dialysis (CAPD)
Sites / Locations
- Universtiy Hospital Maastricht
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
NT-proBNP guided treatment group
Clinically guided arm
In this group, management was guided by an individually set NT-proBNP, defined by the lowest level at discharge or 2 weeks thereafter. If NT-proBNP levels were elevated above the individually set NT-proBNP interventions were performed according to the ESC heart failure guidelines.
Heart failure treatment guided by clinical assessment.